February, 2003
© 2000 Scott S. Emerson, M.D., Ph.D.
Session 4: 59
Case Study 1: Idarubicin in AML
Chronology
Several informal analyses of the data
Formal analysis of the data when N=45 per arm
·CR rate - Ida: 35/45 (78%); Dnr: 25/45 (56%)
·Retrospective adoption of O’Brien-Fleming design
·Trial continued
Formal analysis of the data when N=65 per arm
·CR rate - Ida: 51/65 (78%); Dnr: 38/65 (58%)
·Trial stopped